Novartis $2 million gene therapy for rare disorder is world\'s most expensive drug

Novartis $2 million gene therapy for rare disorder is world's most expensive drug

17:05 EDT 24 May 2019 | Reuters

ZURICH/NEW YORK - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.

Novartis $2 million gene therapy for rare disorder is world\'s most expensive drug

Novartis $2 million gene therapy for rare disorder is world's most expensive drug

More From BioPortfolio on "Novartis $2 million gene therapy for rare disorder is world's most expensive drug"